1
|
Bhasin AA, Molnar AO, McArthur E, Nash DM, Busse JW, Cooper R, Heale E, Ip J, Pang J, Blake PG, Garg AX, Kurdyak P, Kim SJ, Sultan H, Walsh M. Mental health and addiction service utilization among people living with chronic kidney disease. Nephrol Dial Transplant 2023:gfad240. [PMID: 38017620 DOI: 10.1093/ndt/gfad240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2023] Open
Abstract
BACKGROUND Mental health problems, particularly anxiety and depression, are common in patients with chronic kidney disease (CKD), and negatively impact quality of life, treatment adherence, and mortality. However, the degree to which mental health and addictions services are utilized by those with CKD is unknown. We examined the history of mental health and addictions service use of individuals across levels of kidney function. METHODS We performed a population-based cross-sectional study using linked healthcare databases from Ontario, Canada from 2009 to 2017. We abstracted the prevalence of individuals with mental health and addictions service use within the previous 3 years across levels of kidney function (eGFR$\ \ge $60, 45 to < 60, 30 to < 45, 15 to < 30, <15 mL/min per 1.73m2 and maintenance dialysis). We calculated prevalence ratios (PR) to compare prevalence across kidney function strata, while adjusting for age, sex, year of cohort entry, urban versus rural location, area-level marginalization, and Charlson comorbidity scores. RESULTS Of 5 956 589 adults, 9% (n = 534 605) had an eGFR<60 mL/min per 1.73m2 or were receiving maintenance dialysis. Fewer individuals with eGFR < 60 had a history of any mental health and addictions service utilization (crude prevalence range 28% to 31%), compared to individuals with eGFR ≥ 60 (35%). Compared to eGFR ≥ 60, the lowest prevalence of individuals with any mental health and addictions service utilization was among those with eGFR 15 to < 30 (adjusted PR 0.86, 95% CI 0.85 to 0.88), eGFR < 15 (adjusted PR 0.81, 95% CI 0.76 to 0.86) and those receiving maintenance dialysis (adjusted PR 0.83, 95% CI 0.81 to 0.84). Less use of outpatient services accounted for differences in service utilization. CONCLUSIONS Mental health and addictions service utilization is common but less so in individuals with advanced CKD in Ontario, Canada.
Collapse
Affiliation(s)
- Arrti A Bhasin
- Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada
- ICES, ON, Canada
| | - Amber O Molnar
- Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada
- ICES, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
- Population Health Research Institute, Hamilton, ON, Canada
| | - Eric McArthur
- ICES, ON, Canada
- Lawson Health Research Institute, London Health Sciences Centre, London, Ontario, Canada
| | - Danielle M Nash
- ICES, ON, Canada
- Lawson Health Research Institute, London Health Sciences Centre, London, Ontario, Canada
| | - Jason W Busse
- Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada
- Department of Anesthesia, McMaster University, Hamilton, ON, Canada
| | - Rebecca Cooper
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Esti Heale
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Jane Ip
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Jocelyn Pang
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| | - Peter G Blake
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
- Department of Medicine, London Health Sciences Centre, London, ON, Canada
| | - Amit X Garg
- Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada
- ICES, ON, Canada
- Population Health Research Institute, Hamilton, ON, Canada
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
- Department of Medicine, London Health Sciences Centre, London, ON, Canada
| | - Paul Kurdyak
- ICES, ON, Canada
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
- Center for Addiction and Mental Health, Toronto, Ontario, Canada
| | - S Joseph Kim
- ICES, ON, Canada
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
- Department of Medicine, University Health Network, Toronto, ON, Canada
| | - Heebah Sultan
- ICES, ON, Canada
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
| | - Michael Walsh
- Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada
- Department of Medicine, McMaster University, Hamilton, ON, Canada
- St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada
- Population Health Research Institute, Hamilton, ON, Canada
- Ontario Renal Network, Ontario Health, Toronto, ON, Canada
| |
Collapse
|
2
|
Zhang H, Pang J, Zhang Y, Ma Y, Fan F, Liu H. [AZD9291 suppresses proliferation and migration of nasopharyngeal carcinoma cells by inhibiting the PI3K-AKT-mTOR pathway]. Nan Fang Yi Ke Da Xue Xue Bao 2022; 42:1403-1409. [PMID: 36210715 DOI: 10.12122/j.issn.1673-4254.2022.09.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the effects of AZD9291 on the proliferation and migration of nasopharyngeal carcinoma cells. METHODS Nasopharyngeal carcinoma HNE1 and CNE2Z cells were treated with AZD9291 at the doses of 0.5, 1, 2, 4, and 8 μmol/L and at the doses of 1, 2, 4, 8, and 16 μmol/L, respectively. Cell survival was measured using CCK8 assay, and proliferation inhibition of the cells after AZD9291 treatment was examined with colony-forming assay; the cell repair and migration abilities were determined using scratch assay and Transwell experiment. The expressions of EGFR-related signaling proteins and migration-related proteins were detected using Western blotting. RESULTS The results of CCK8 assay and colonyforming assay showed that AZD9291 significantly inhibited the viability and proliferation of both HNE1 and CNE2Z cells (P < 0.01). AZD9291 treatment also attenuated the migration ability of HNE1 and CNE2Z cells (P < 0.01). Western blotting showed that, as the concentration of AZD9291 increased, the expression levels of the proteins involved in the PI3K-AKT-mTOR signaling pathway were lowered progressively (P < 0.01), resulting in inhibition of migration of HNE1 and CNE2Z cells (P < 0.01). CONCLUSION AZD9291 suppresses proliferation and attenuates repair and migration capacities of nasopharyngeal carcinoma cells by inhibiting the EGFR/PI3K/AKT/mTOR signaling pathway, suggesting the potential value of AZD9291 in the treatment of nasopharyngeal carcinoma.
Collapse
Affiliation(s)
- H Zhang
- School of Clinical Medicine, Bengbu Medical College, Bengbu 233000, China
| | - J Pang
- School of Pharmacy, Bengbu Medical College//Anhui Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu 233000, China
| | - Y Zhang
- School of Pharmacy, Bengbu Medical College//Anhui Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu 233000, China
| | - Y Ma
- School of Pharmacy, Bengbu Medical College//Anhui Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu 233000, China
| | - F Fan
- School of Pharmacy, Bengbu Medical College//Anhui Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu 233000, China
| | - H Liu
- School of Pharmacy, Bengbu Medical College//Anhui Biochemical Pharmaceutical Engineering Technology Research Center, Bengbu 233000, China
| |
Collapse
|
3
|
Cao J, Liu K, Li K, Hu W, Pang J, Sun P, Zhang S, Zhang X, Pang F, You D. 720P Integrative genomic analysis of matched primary and recurrent tumors reveals molecular characteristics of hepatocellular carcinoma with short-term recurrence. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
4
|
Han Y, Lu S, Zhao R, Xu Y, Chen Y, Xiang C, Wu Q, Chen S, Pang J, Shang Z, Zhao J, Bao H, Shao Y. EP16.03-044 Genomic Evidence Depicting Clonal Evolution of Lung Adenosquamous Carcinoma. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
5
|
Brett T, Marquina C, Radford J, Heal C, Hespe C, Gill G, Sullivan D, Zomer E, Morton J, Watts G, Pang J, Ademi Z. Enhancing the potential for increased primary care role in familial hypercholesterolaemia detection and management: Cost-effectiveness and return on investment. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Ying Q, Croyal M, Chan D, Blanchard V, Pang J, Krempf M, Watts G. Postprandial apolipoprotein(a) metabolism in familial hypercholesterolaemia: Therapeutic effect of omega-3 fatty acid supplementation. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.06.416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
7
|
Bi Y, Ge L, Ren X, Pang J, Zhao Y, Liang Z. Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma. Clin Transl Oncol 2022; 24:941-949. [PMID: 35064455 DOI: 10.1007/s12094-021-02744-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Accepted: 11/29/2021] [Indexed: 11/26/2022]
Abstract
PURPOSE Cutaneous angiosarcoma (CAS) is a rare but typically aggressive malignant vascular neoplasm of the skin. Tumor microenvironment (TME) of CAS and its associations with baseline clinicopathological features and patient outcomes are very important, especially when considering the recent advances in understanding of the tumor biology. METHODS/PATIENTS We retrospectively reviewed medical records of patients who underwent surgical resection for CAS at a tertiary Hospital. The pretreated specimens were evaluated by immunohistochemistry for programmed cell death protein 1 (PD-1) and its ligand (PD-L1), densities of tumor infiltrative lymphocytes (TILs) (CD3+, CD4+, CD8+, CD45RO+, FoxP3+), as well as c-MYC and Ki-67 expressions. Overall survival (OS) was estimated by Kaplan-Meier method and compared with Log-rank test. RESULTS A total of 21 CAS patients were identified. Median age was 67 (ranges: 20-81) years, 14 (66.7%) were male, and over 50% had lesions of scalp. Histopathological examination showed a predominantly spindle cell type (57.1%). All patients underwent surgery, 16 (76.2%) were treated further. PD-L1 was positively stained (> 1%) in tumor cells (42.9%) and TILs (23.8%). PD-1 expression (> 1%) was identified in TILs of 11 (52.4%) cases. PD-1/PD-L1 expressions were significantly associated with the higher densities of CD3+, CD4+, CD8+, CD45RO+, and Foxp3+ TILs, but not with patient characteristics or c-MYC or Ki-67 expression. Median OS was 18.5 months (95% CI 6.0-35.9), although no prognostic significance was observed with respect to any clinicopathological features. CONCLUSION We characterized TME and its clinical and prognostic association in CAS. PD-1/PD-L1 expressions were significantly associated with TILs subtypes but not with OS.
Collapse
Affiliation(s)
- Y Bi
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China
- Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Medicine, Tsinghua University, No. 168 Litang Road, Changping District, Beijing, 102218, China
| | - L Ge
- Department of Pathology, Weifang People's Hospital, Weifang, 261041, China
| | - X Ren
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China
| | - J Pang
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China
| | - Y Zhao
- Department of Dermatology, Beijing Tsinghua Changgung Hospital, School of Medicine, Tsinghua University, No. 168 Litang Road, Changping District, Beijing, 102218, China.
| | - Z Liang
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing, 100730, China.
| |
Collapse
|
8
|
Noonan M, Pang J, Li T, Bhuiyan M, Nathan C, Yim M. Access to Care for Head and Neck Cancer Patients: The Influence of Expanded Medicaid in Louisiana. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2021.12.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Galante J, Adeleke S, Wong M, Choy A, Lees K, Edwards A, Raman R, Thomas C, Taylor H, Pang J, Ramadan A, Bianchini D, Clarke A, Naji M, Ellul G, Brulinski P. Use of Novel Imaging for Patient Selection for Stereotactic Ablative Radiotherapy (SABR) in Oligometastatic Prostate Cancer (PCa): Does the PET Tracer Make a Difference? Clin Oncol (R Coll Radiol) 2022. [DOI: 10.1016/j.clon.2021.11.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
10
|
Lacaze P, Marquina C, Tiller J, Riaz M, Sturm A, Nelson M, Ference B, Pang J, Watts G, Nicholls S, Zoungas S, Liew D, McNeil J, Ademi Z. Population Genomic Screening of Young Adults for Familial Hypercholesterolaemia: A Cost-Effectiveness Analysis. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Huangfu G, Jaltotage B, Pang J, Lan N, Abraham A, Otto J, Ihdayhid A, Rankin J, Watts G, Ayonrinde O, Dwivedi G. CT Evaluation of Hepatic Fat: A Novel Marker for High-Risk Coronary Atherosclerosis in Familial Hypercholesterolaemia. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Ademi Z, Marquina C, Lacaze P, Tiller J, Riaz M, Sturm AC, Nelson M, Ference BA, Pang J, Watts GF, Nicholls SJ, Zoungas S, Liew D, McNeil J. Population genomic screening of all young adults in Australia to detect familial hypercholesterolemia: a cost-effectiveness analysis. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2727] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Heterozygous familial hypercholesterolemia (FH) is a highly-penetrant, autosomal dominant monogenic disorder that causes elevated plasma low-density cholesterol (LDL-C) levels and risk of premature coronary heart disease (CHD). To date, the cost-effectiveness of the emerging strategy of genomic screening of adult populations for FH has not been investigated.
Purpose
To assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolemia (FH).
Methods
We designed a decision analysis model to compare the current standard of care for heterozygous FH diagnosis in Australia (opportunistic cholesterol screening and genetic cascade testing) with population genomic screening of adults aged 18–40 years to detect pathogenic variants in the LDLR/APOB/PCSK9 genes. The model captured morbidity/mortality due to coronary heart disease (CHD) over a lifetime horizon, from a healthcare perspective. Risk of CHD, treatment effects, prevalence, and healthcare costs were estimated from published studies. Outcomes included quality adjusted life years (QALYs), costs and incremental cost-effectiveness ratio (ICER), discounted 5% annually. Sensitivity analyses were undertaken to explore the impact of key input parameters on the robustness of the model. The model structure was designed to be transferable to countries with different healthcare systems.
Results
Over the lifetime of the population (4,167,768 men; 4,129,961 women), the model estimated a gain of 62,722 years of life lived and 73,959 QALYs due to CHD prevention. Population genomic screening for FH would be cost-effective from a healthcare perspective if the cost per test was ≤AU$300 (∼US$233) which would yield an ICER AU$28,000 cost-saving.
Conclusion
Based on our model, offering population genomic screening to all young adults to detect FH could be cost-effective in the Australian healthcare system, at testing costs that are currently feasible.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): This work was supported by the Australian National Heart Foundation and Monash University Faculty of Medicine, Nursing and Health Sciences Results from scenario analysesResults from Monte Carlo simulations
Collapse
Affiliation(s)
- Z Ademi
- Monash University, Melbourne, Australia
| | | | - P Lacaze
- Monash University, Melbourne, Australia
| | - J Tiller
- Monash University, Melbourne, Australia
| | - M Riaz
- Monash University, Melbourne, Australia
| | - A C Sturm
- Genomic Medicine Institute, Geisinger, United States of America
| | - M Nelson
- Monash University, Melbourne, Australia
| | - B A Ference
- University of Cambridge, Cambridge, United Kingdom
| | - J Pang
- The University of Western Australia, Perth, Australia
| | - G F Watts
- The University of Western Australia, Perth, Australia
| | | | - S Zoungas
- Monash University, Melbourne, Australia
| | - D Liew
- Monash University, Melbourne, Australia
| | - J McNeil
- Monash University, Melbourne, Australia
| |
Collapse
|
13
|
Ying Q, Pang J, Chan DC, Barrett PHR, Watts GF. PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle, covalently bound to apolipoprotein(a) [apo(a)]. Recent trials show that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, such as alirocumab, decrease plasma Lp(a) levels and risk of atherosclerotic cardiovascular disease (ASCVD). The kinetic mechanism for lowering Lp(a) by PCSK9 inhibitors may differ according to pre-treatment apo(a) levels.
Purpose
We investigated the effect of alirocumab on Lp(a) metabolism in 21 long-term statin-treated patients [Lp(a) >0.5 g/L in all] with moderate-high (n=10) and high (n=11) apo(a) concentrations according to a cutoff of median apo(a) levels of 145 nmol/L.
Methods
Apo(a) kinetics were studied before and after 12-week treatment with alirocumab (150 mg subcutaneously fortnightly). Apo(a) fractional catabolic rate (FCR) and production rate (PR) were determined using intravenous D3-leucine administration, mass spectrometry and compartmental modelling.
Results
The plasma concentration and PR of apo(a) were significantly higher in patients with high apo(a) than in patients with moderate-high apo(a) levels (273±30 nmol/L vs 130±4.7 nmol/L and 6.0±0.69 nmol/kg/day vs 2.6±0.15 nmol/kg/day, respectively; P<0.001). The FCR of apo(a) was not significantly different between two groups (0.48±0.02 pools/day vs 0.45±0.01 pools/day, P>0.05). In patients with moderate-high apo(a) levels, alirocumab significantly lowered plasma apo(a) levels (−17%, P<0.01) and increased the FCR of apo(a) (+26%, P<0.001), but did not alter apo(a) PR. In contrast, alirocumab significantly lowered plasma apo(a) concentrations (−31%, P<0.001) via a dual mechanism that increased apo(a) FCR (+31%, P<0.001) and lowered PR (−9%, P<0.05) in patients with high apo(a) levels. The reductions in apo(a) concentration and PR with alirocumab in the high apo(a) group remained significant after adjusting for background statin when compared with patients with moderate-high apo(a) levels (P<0.05).
Conclusions
In statin-treated patients with elevated Lp(a), alirocumab may lower elevated plasma Lp(a) concentrations by a dual mechanism of increasing the catabolism and decreasing the production of Lp(a) particles, specifically in patients with relatively high apo(a) concentrations.
Funding Acknowledgement
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): This independent research was funded by an Investigator Initiated Study Concept Research Grant from Regeneron Pharmaceuticals and Sanofi (Protocol No. LPS 14508). Figure 1Figure 2
Collapse
Affiliation(s)
- Q Ying
- The University of Western Australia, School of Medicine, Faculty of Health and Medical Sciences, Perth, Australia
| | - J Pang
- The University of Western Australia, School of Medicine, Faculty of Health and Medical Sciences, Perth, Australia
| | - D C Chan
- The University of Western Australia, School of Medicine, Faculty of Health and Medical Sciences, Perth, Australia
| | - P H R Barrett
- University of New England, Faculty of Medicine and Health, Armidale, Australia
| | - G F Watts
- The University of Western Australia, School of Medicine, Faculty of Health and Medical Sciences, Perth, Australia
| |
Collapse
|
14
|
Xu L, Huang F, Zhang Y, Niu W, Pang J, Li S, Li X. [ Chuanxiong Rhizoma inhibits brain metastasis of lung cancer through multiple active ingredients acting on multiple targets, pathways and biological functions]. Nan Fang Yi Ke Da Xue Xue Bao 2021; 41:1319-1328. [PMID: 34658345 DOI: 10.12122/j.issn.1673-4254.2021.09.05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To explore the molecular mechanism mediating the inhibitory effect of Chuanxiong Rhizoma against brain metastasis of lung cancer using network pharmacology methods and molecular docking. METHODS The chemical components of Chuanxiong Rhizoma and their targets were obtained through the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database. The relevant targets for brain metastasis of lung cancer were screened using the GeneCards database. Clusterpro-filerR package was used to perform GO and KEGG enrichment analysis. Cytoscape and STRING database were used to construct the "active ingredient-target-disease" network and protein-protein interaction (PPI) network of Chuanxiong Rhizoma. The core components of Chuanxiong Rhizoma and their targets in the treatment of lung cancer brain metastasis were screened based on the topological parameters, and the results were verified using molecular docking and in Chuanxiong extract- treated human lung cancer PC9 cells by detecting the core target with Western blotting. RESULTS Forty-eight active ingredients of Chuanxiong Rhizoma including (Z)-ligustilide, butylphthalide, oleic acid, and myricetone were screened, which target 49 proteins including INS, BDNF, FOS, VEGFA, PTGS2, ESR1, MAPK14, and PTGS1. These proteins participated in 57 biological functions such as nuclear receptor activity, ligand activation, and transcription factor activity, involving 40 signaling pathways such as prolactin signaling pathway, breast cancer, and etrogen signaling. The results of molecular docking showed that myricetone, butylphthalide, 4-hydroxy-3 butylphthalide, (Z)-ligustilide, and ligustalide-E, among others, had strong affinities to 7 cores targets including BDNF, FOS, PTGS2, and MAPK14. In PC9 cells, treatment with Chuanxiong Rhizoma extract resulted in significant reductions in the phosphorylation levels of PI3K, Akt and VEGF (P < 0.01). CONCLUSION Chuanxiong Rhizoma contains multiple active ingredients against brain metastasis lung cancer, and these ingredients act on multiple targets involving multiple signal pathways and biological functions.
Collapse
Affiliation(s)
- L Xu
- Bengbu Medical College, Bengbu 233030, China
| | - F Huang
- Bengbu Medical College, Bengbu 233030, China
| | - Y Zhang
- Bengbu Medical College, Bengbu 233030, China
| | - W Niu
- Bengbu Medical College, Bengbu 233030, China
| | - J Pang
- Bengbu Medical College, Bengbu 233030, China
| | - S Li
- Bengbu Medical College, Bengbu 233030, China
| | - X Li
- Bengbu Medical College, Bengbu 233030, China.,Key Laboratory of Anhui Province for New Technology of Chinese Medicine Decoction Pieces Manufacturing, Bozhou 236800, China.,Postdoctoral Workstation of Anhui Xiehecheng Pharmaceutical Decoction Pieces Co., Ltd., Bozhou 236800, China
| |
Collapse
|
15
|
Chakraborty A, Pang J, Chan D, Watts G. Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) in patients with elevated lipoprotein(a) attending a clinic. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
16
|
Ge X, Zhang Y, Huang F, Wu Y, Pang J, Li X, Fan F, Liu H, Li S. EGFR tyrosine kinase inhibitor Almonertinib induces apoptosis and autophagy mediated by reactive oxygen species in non-small cell lung cancer cells. Hum Exp Toxicol 2021; 40:S49-S62. [PMID: 34219533 DOI: 10.1177/09603271211030554] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022]
Abstract
Almonertinib, a new third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is highly selective to EGFR T790M-mutant non-small cell lung cancer (NSCLC). However, there is no available information on the form and molecular mechanism of Almonertinib-induced death in NSCLC cells. Herein, CCK-8 and colony formation assays, flow cytometry, electron microscopy, and western blots assay showed that Almonertinib inhibited NSCLC cells growth and proliferation by inducing apoptosis and autophagy which can be inhibited by a broad spectrum of caspase inhibitor Z-VAD-fmk or autophagy inhibitor chloroquine. Importantly, Almonertinib-induced autophagy was cytoprotective in NSCLC cells, and the blockade of autophagy improved cell apoptosis. In addition, Almonertinib increased reactive oxygen species (ROS) generation and clearance of ROS through pretreatment with N-acetyl-L-cysteine (NAC) inhibited the decrease of cell viability, apoptosis and increase of LC3-II induced by Almonertinib. The results of Western blot showed that both EGFR activity and downstream signaling pathways were inhibited by Almonertinib. Taken together, these findings indicated that Almonertinib induced apoptosis and autophagy by promoting ROS production in NSCLC cells.
Collapse
Affiliation(s)
- X Ge
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China
| | - Y Zhang
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China
| | - F Huang
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China
| | - Y Wu
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China
| | - J Pang
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China
| | - X Li
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China
| | - F Fan
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China
| | - H Liu
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China
| | - S Li
- Faculty of Pharmacy, Bengbu Medical College, Bengbu, Anhui, People's Republic of China
| |
Collapse
|
17
|
Jaltotage B, Pang J, Abraham A, Krishnan A, Chow B, Ihdayhid A, Mohd S, Watts G, Dwivedi G. Value Of Atherosclerotic Plaque Characteristics And Pericoronary Adipose Tissue In Predicting Outcomes In Familial Hypercholesterolemia: Should CCTA Be Carried Out In All Adult Patients With FH? J Cardiovasc Comput Tomogr 2021. [DOI: 10.1016/j.jcct.2021.06.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Jaltotage B, Abraham A, Pang J, Krishnan A, Chow B, Ihdayhid A, Lu J, Watts G, Dwivedi G. Can We Predict High-risk Plaques In Familial Hypercholesterolemia Using Clinical Variables And Coronary Artery Calcium. J Cardiovasc Comput Tomogr 2021. [DOI: 10.1016/j.jcct.2021.06.274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
19
|
Li Q, Cen B, Huang W, Chen J, Chen Z, Pang J, Fu W, He S, Ji A. [Development and functional validation of a nano-delivery system of miR-16/polypeptide targeting ovarian cancer cells]. Nan Fang Yi Ke Da Xue Xue Bao 2021; 41:736-746. [PMID: 34134962 DOI: 10.12122/j.issn.1673-4254.2021.05.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To develop a nano-delivery system for targeted delivery of miR-16/polypeptide for enhancing cisplatin sensitivity of ovarian cancer. OBJECTIVE R9-SS-R9 and cRGD-R9-SS-R9 peptides were synthesized and self-assembled with miR-16 molecules to form a nano-delivery system. The stability, particle size, potential and morphology of the nanoparticles were determined by agarose gel electrophoresis, particle size potentiometer and transmission electron microscopy. CCK-8 assay was used to assess the toxicity of the polypeptides in ovarian cancer cells. Stem loop qRT-PCR and living cell imaging were used to verify the uptake efficiency and intracellular distribution of the nanoparticles. Flow cytometry and Western blotting were performed to verify the effect of the nanoparticles for enhancing cisplatin sensitivity of ovarian cancer cells and explore the possible mechanism. OBJECTIVE R9-SS-R9/miR-16 and cRGD-R9-SS-R9/miR-16 nanoparticles were successfully prepared. The nanoparticles, with a particle size below 150 nm, a dispersity index less than 0.1 and a potential of about 40 mV, showed a good serum stability. The polypeptide material had no obvious cytotoxicity. The miR-16/polypeptide nanoparticles could be efficiently absorbed by human ovarian cancer cells and were distributed in the cytoplasm. The nanoparticles significantly increased the intracellular expression level of miR-16 (P < 0.001) and decreased the expression of Bcl-2 and Chk-1 proteins in ovarian cancer cells, thus enabling miR-16 to promote apoptosis and enhance cisplatin sensitivity of the cells. OBJECTIVE We successfully prepared a miR-16/polypeptide nano-delivery system for targeted delivery of miR-16 to ovarian cancer cells for enhancing cisplatin sensitivity of the cancer cells.
Collapse
Affiliation(s)
- Q Li
- School of Pharmacy, Southern Medical University, Guangzhou 510515, China.,Department of Pharmacy, Nanhai Hospital Affiliated to Southern Medical University, Foshan 528200, China
| | - B Cen
- Department of Radiation Oncology, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou 510095, China
| | - W Huang
- School of Pharmacy, Southern Medical University, Guangzhou 510515, China
| | - J Chen
- School of Pharmacy, Southern Medical University, Guangzhou 510515, China
| | - Z Chen
- School of Pharmacy, Southern Medical University, Guangzhou 510515, China
| | - J Pang
- School of Pharmacy, Southern Medical University, Guangzhou 510515, China
| | - W Fu
- School of Pharmacy, Southern Medical University, Guangzhou 510515, China
| | - S He
- Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
| | - A Ji
- Department of Pharmacy, Nanhai Hospital Affiliated to Southern Medical University, Foshan 528200, China
| |
Collapse
|
20
|
Chakraborty A, Pang J, Chan D, Watts G. Cardiovascular and behavioural risk factors in families with elevated lipoprotein(a)[Lp(a)]. Eur J Prev Cardiol 2021. [DOI: 10.1093/eurjpc/zwab061.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background/Introduction
Elevated lipoprotein(a)[Lp(a)] is an inherited and independent risk factor for atherosclerotic cardiovascular diseases (ASCVD). However, it is an under detected condition with no specific therapy available at present for lowering Lp(a). Hence, identifying the distribution of modifiable cardiovascular and behavioural risk factors is important for implementing an effective intervention programme to mitigate the overall risk of ASCVD in high-risk individuals with elevated Lp(a).
Purpose
The primary aim was to describe and compare the distribution of modifiable cardiovascular and behavioural risk factors in both index cases and their relatives with elevated Lp(a) identified through cascade testing at the Lipid Disorders Clinic, Royal Perth Hospital.
Methods
We studied 51 index cases and 71 relatives cascade tested with elevated Lp(a) (≥0.5 g/L). Questionnaires were completed concerning aspects of cardiovascular health (cholesterol level, blood pressure and blood glucose level) and behavioural health metrics (diet, smoking, physical activity, body-mass-index [BMI]). Lp(a) was measured by an immunoassay having minimal dependence on apolipoprotein(a) isoform size. The health metrics were described as proportions and statistical analyses performed using Student’s t-test or Chi-square where appropriate.
Results
Compared with the index cases, a higher proportion of their affected relatives were female (62% vs 43%, p = 0.039), younger (43 years vs 53 years, p < 0.001) and had lower Lp(a) levels (1.03 g/L vs 1.12 g/L, p = 0.003). A lower proportion of the affected relatives were treated for dyslipidaemia (31% vs 96%, p < 0.001). The affected relatives also had a lower incidence of ASCVD events (3% vs 37%, p < 0.001), hypertension (21% vs 43%, p = 0.003), and lower HbA1c levels (5.3% vs 5.9%, p = 0.031) compared with index cases. Additionally, a larger proportion of the affected relatives had ideal cardiovascular health (35% vs 14%, p = 0.008) compared with their index cases. However, more than half of the index cases and their relatives did not maintain a healthy diet (59% and 69%, respectively) and an ideal BMI (68% and 59%, respectively).
Conclusion(s)
Although the younger affected relatives with elevated Lp(a) have a lower cardiovascular risk compared with the index cases, a focus on modifiable behavioural changes, such as a healthy diet and an ideal body weight, is still required to mitigate the overall risk of ASCVD.
Collapse
Affiliation(s)
| | - J Pang
- University of Western Australia, Perth, Australia
| | - D Chan
- University of Western Australia, Perth, Australia
| | - G Watts
- Royal Perth Hospital, Lipid Disorders Clinic, Internal Medicine, Department of Cardiology, Perth, Australia
| |
Collapse
|
21
|
Jaltotage B, Pang J, Abraham A, Krishnan A, Chow B, Ihdayhid A, Mohd S, Watts G, Dwivedi G. Value of Atherosclerotic Plaque Characteristics and Pericoronary Adipose Tissue in Predicting Outcomes in Familial Hypercholesterolaemia: Should CCTA be Carried out in all Adult Patients With FH? Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.06.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
22
|
Jaltotage B, Abraham A, Pang J, Krishnan A, Chow B, Ihdayhid A, Lu J, Watts G, Dwivedi G. Can we Predict High-Risk Plaques in Familial Hypercholesterolaemia Using Clinical Variables and Coronary Artery Calcium? Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.06.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
23
|
Ademi Z, Norman R, Pang J, Liew D, Zoungas S, Sijbrands E, Ference B, Wiegman A, Watts G. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment? Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3535] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
There are no studies that have specifically investigated the cost-effectiveness of cascade screening of children for heterozygous familial hypercholesterolemia (FH) and treatment of affected individuals with statins to prevent coronary heart disease (CHD).
Purpose
This study explores the cost-effectiveness of this strategy from the perspective of the Australian public healthcare system.
Methods
A lifetime Markov model with four health states (Alive without CHD, Alive with CHD, Dead from fatal CHD, and Dead from other causes) was developed to simulate the progression of ten- year-old children screened for FH and treated immediately with statins if found to have FH. The underlying prevalence of FH in this target population was assumed to be 56.8%, and the sensitivity and specificity of testing was 100%. The comparator was usual care, which assumed that subjects started statins spontaneously at a later point or when they experienced a cardiovascular event. The effect of reducing low-density lipoprotein cholesterol (LDL-C) on the risk of a first event at each age assumed that risk was proportional to total lifetime exposure and was implemented using Mendelian randomisation analysis data. Cost and other outcome data were sourced from published sources. Outcome of interests were costs in Australian dollars (AUD), life years gained (LYG) and quality-adjusted life years (QALYs) gained, as well as incremental cost-effectiveness ratios (ICERs) of costs per LYG and per QALY gained. All future costs and outcomes were discounted by 5% annually.
Results
Undiscounted results showed that compared with usual care, cascade screening of ten year-old children for FH and initiation of treatment of affected individuals saved 7.77 LYG and 7.53 QALYs per person over a lifetime. With 5% annual discounting, there were 0.97 LYG and 1.07 QALYs gained per person, at an additional cost of $3,244. These equated to ICERs of $3334 per LYG and $3023 per QALY gained. The equivalent ICERs in USD would be $5089 per LYG gained and $4615 per QALY gained. Sensitivity analysis showed the results to be robust.
Conclusions
Compared to usual care, cascade screening of ten year old children for FH and treating affected individuals is likely to be highly cost-effective.
Table 1. Granular cost and benefit data
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- Z Ademi
- Monash Centre of Cardiovascular Research & Education in Therapeutics, Melbourne, Australia
| | - R Norman
- Curtin University, Perth, Australia
| | - J Pang
- The University of Western Australia, Perth, Australia
| | - D Liew
- Monash Centre of Cardiovascular Research & Education in Therapeutics, Melbourne, Australia
| | - S Zoungas
- Monash University, Melbourne, Australia
| | - E Sijbrands
- Erasmus University Medical Centre, Rotterdam, Netherlands (The)
| | - B.A Ference
- University of Cambridge, Cambridge, United Kingdom
| | - A Wiegman
- Amsterdam University Medical Center, Amsterdam, Netherlands (The)
| | - G Watts
- The University of Western Australia, Perth, Australia
| |
Collapse
|
24
|
Jiang D, Liu H, Zhu G, Li X, Fan L, Yu Z, Wang S, Rhen J, Yin Y, Gu Y, Xu X, Fisher E, Ge J, Xu Y, Pang J. PHACTR1, a pro-atherosclerotic mechanosensitive PPARgamma corepressor in endothelial cells. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Numerous genome-wide association studies revealed that SNPs at phosphatase and actin regulator 1 (PHACTR1) locus are strongly correlated with coronary artery disease (CAD). However, the mechanism linking these variants to CAD remains uncertain.
Purpose
We studied the biological functions and molecular mechanisms of PHACTR1 in atherosclerosis.
Methods and results
Analysis of GTEx database showed that CAD-related SNPs in PHACTR1 are cis-eQTLs for PHACTR1 in arteries. Therefore, we generated Phactr1 knockout mice and crossed them with apolipoprotein E-deficient (ApoE−/−) mice to induce atherosclerosis by high-fat/high-cholesterol (HF-HC) diet. Phactr1 deficiency significantly inhibited atherosclerosis with decreased inflammatory cell infiltration. Western blot showed that PHACTR1 was restricted to endothelial cells (ECs) in mice. Mechanistically, RNAseq of aortic ECs revealed that the major molecular function of PHACTR1 was transcriptional regulation. PPARγ/RXRα was the top transcription factor, and PPARγ target gene expression substantially increased in Phactr1−/− mice. Moreover, we generated endothelial cell specific Phactr1−/−, ApoE−/− mice and found decreased atherosclerotic plaque area in aortic sinus. In vitro, PHACTR1 associated with PPARγ and inhibited PPARγ transcriptional activity. The inhibitory effect of PHACTR1 on PPARγ required its shuttling from cytosol to nucleus triggered by disturbed flow, a well-established pro-atherosclerotic stimulus.
Conclusion
Our results identified PHACTR1 as a mechanosensitive corepressor of PPARγ in ECs to promote atherosclerosis. Endothelial PHACTR1 is a potential therapeutic target for atherosclerosis treatment.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): National Natural Science Foundation of China (NSFC), China Postdoctoral Science Foundation (CPSF)
Collapse
Affiliation(s)
- D Jiang
- Tongji University School of Medicine, Department of Cardiology, Pan-vascular Research Institute, Shanghai Tenth People's Hospital, Shanghai, China
| | - H Liu
- Tongji University School of Medicine, Department of Cardiology, Pan-vascular Research Institute, Shanghai Tenth People's Hospital, Shanghai, China
| | - G Zhu
- Tongji University School of Medicine, Department of Cardiology, Pan-vascular Research Institute, Shanghai Tenth People's Hospital, Shanghai, China
| | - X Li
- Tongji University School of Medicine, Department of Cardiology, Pan-vascular Research Institute, Shanghai Tenth People's Hospital, Shanghai, China
| | - L Fan
- Tongji University School of Medicine, Department of Cardiology, Pan-vascular Research Institute, Shanghai Tenth People's Hospital, Shanghai, China
| | - Z Yu
- Tongji University School of Medicine, Department of Cardiology, Pan-vascular Research Institute, Shanghai Tenth People's Hospital, Shanghai, China
| | - S Wang
- University of Rochester School of Medicine and Dentistry, Aab Cardiovascular Research Institute and Department of Medicine, Rochester, United States of America
| | - J Rhen
- University of Rochester School of Medicine and Dentistry, Aab Cardiovascular Research Institute and Department of Medicine, Rochester, United States of America
| | - Y Yin
- Tongji University School of Medicine, Department of Cardiology, Pan-vascular Research Institute, Shanghai Tenth People's Hospital, Shanghai, China
| | - Y Gu
- Shanghai Naturethink Life Science&Technology Co., Itd, Shanghai, China
| | - X Xu
- University of Rochester School of Medicine and Dentistry, Aab Cardiovascular Research Institute and Department of Medicine, Rochester, United States of America
| | - E Fisher
- New York University School of Medicine, Division of Cardiology, Department of Medicine, New York, United States of America
| | - J Ge
- Tongji University School of Medicine, Department of Cardiology, Pan-vascular Research Institute, Shanghai Tenth People's Hospital, Shanghai, China
| | - Y Xu
- Tongji University School of Medicine, Department of Cardiology, Pan-vascular Research Institute, Shanghai Tenth People's Hospital, Shanghai, China
| | - J Pang
- University of Rochester School of Medicine and Dentistry, Aab Cardiovascular Research Institute and Department of Medicine, Rochester, United States of America
| |
Collapse
|
25
|
Li L, Tang S, Yin J, Pang J, Bao H, Ge H, Liu Y, Wang J, Dong L, Mu D, Yuan S, Wu X, Wang X, Shao Y, Yu J, Yuan S. Molecular Biomarkers for Chemoradiotherapy Response in Unresectable Limited Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.2074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
26
|
Edelman R, Leloudas N, Pang J, Bailes J, Merrell R, Koktzoglou I. Twofold improved tumor-to-brain contrast using a novel T1 relaxation-enhanced steady-state (T 1RESS) MRI technique. Sci Adv 2020; 6:6/44/eabd1635. [PMID: 33115747 PMCID: PMC7608787 DOI: 10.1126/sciadv.abd1635] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Accepted: 09/15/2020] [Indexed: 06/11/2023]
Abstract
A technique that provides more accurate cancer detection would be of great value. Toward this end, we developed T1 relaxation-enhanced steady-state (T1RESS), a novel magnetic resonance imaging (MRI) pulse sequence that enables the flexible modulation of T1 weighting and provides the unique feature that intravascular signals can be toggled on and off in contrast-enhanced scans. T1RESS makes it possible to effectively use an MRI technique with improved signal-to-noise ratio efficiency for cancer imaging. In a proof-of-concept study, "dark blood" unbalanced T1RESS provided a twofold improvement in tumor-to-brain contrast compared with standard techniques, whereas balanced T1RESS greatly enhanced vascular detail. In conclusion, T1RESS represents a new MRI technique with substantial potential value for cancer imaging, along with a broad range of other clinical applications.
Collapse
Affiliation(s)
- R Edelman
- Radiology, NorthShore University HealthSystem, 2650 Ridge Ave., Evanston, IL 60201, USA.
- Northwestern Medicine, 251 E. Huron St., Chicago, IL 60611, USA
| | - N Leloudas
- Radiology, NorthShore University HealthSystem, 2650 Ridge Ave., Evanston, IL 60201, USA
| | - J Pang
- Siemens Medical Solutions USA Inc., 737 N. Michigan Ave., Chicago, IL 60611, USA
| | - J Bailes
- University of Chicago Pritzker School of Medicine, 924 E. 57th St., Chicago, IL 60637, USA
- Neurosurgery, NorthShore University HealthSystem, 2650 Ridge Ave., Evanston, IL 60201, USA
| | - R Merrell
- University of Chicago Pritzker School of Medicine, 924 E. 57th St., Chicago, IL 60637, USA
- Neurology, NorthShore University HealthSystem, 2650 Ridge Ave., Evanston, IL 60201, USA
| | - I Koktzoglou
- Radiology, NorthShore University HealthSystem, 2650 Ridge Ave., Evanston, IL 60201, USA
- University of Chicago Pritzker School of Medicine, 924 E. 57th St., Chicago, IL 60637, USA
| |
Collapse
|
27
|
Abstract
Menopause-related symptoms are common problems of middle-aged women that can seriously affect their quality of life. Menopausal hormone therapy (MHT) for climacteric symptoms is the first choice recommended by the International Menopause Society and likewise by other societies and institutions covering this field. However, non-hormonal therapies can be an alternative effective option, especially for women who are not suitable for MHT. Acupuncture is one of the most important methods. With deepening experience of the use of traditional Chinese acupuncture and moxibustion in the improvement of menopause symptoms, more clinical evidence has been obtained to support the effectiveness and safety of this treatment concept that is very often used in China. This review summarizes the evidence for effective treatment of climacteric complaints by acupuncture in recent years, shares the clinical experience of the authors of this review, all of whom head or work in units with daily large numbers of outpatients, and includes, in particular, results from studies performed in the Department of Acupuncture--Moxibustion of Tsinghua University Chuiyangliu Hospital, Beijing, China. In addition, there is a summary about the safety of acupuncture treatment in traditional Chinese medicine.
Collapse
Affiliation(s)
- Y Qin
- Department of Acupuncture-Moxibustion, Tsinghua University Chuiyangliu Hospital, Beijing, China
| | - X Ruan
- Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China.,Department of Women's Health, University Women's Hospital and Research Centre for Women's Health, University of Tuebingen, Tuebingen, Germany
| | - R Ju
- Department of Obstetrics and Gynecology, Tsinghua University Chuiyangliu Hospital, Beijing, China
| | - J Pang
- Department of Acupuncture-Moxibustion, Tsinghua University Chuiyangliu Hospital, Beijing, China
| | - G Zhao
- Department of Obstetrics and Gynecology, Tsinghua University Chuiyangliu Hospital, Beijing, China
| | - X Hu
- Department of Acupuncture-Moxibustion, Tsinghua University Chuiyangliu Hospital, Beijing, China
| |
Collapse
|
28
|
Pang J, Nguyen N, Finegersh A, Ren S, Birmingham A, Xu G, Fisch K, Bafna V, Califano J. Long-read RNA-Seq of human papillomavirus-associated head and neck cancer reveals novel alternatively spliced viral RNA isoforms. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
29
|
Wang X, Chen X, Zhang H, Pang J, Lin J, Xu X, Yang L, Ma J, Ling W, Chen Y. Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease. Diabetes & Metabolism 2020; 46:119-128. [DOI: 10.1016/j.diabet.2019.04.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Revised: 04/28/2019] [Accepted: 04/28/2019] [Indexed: 02/07/2023]
|
30
|
Li Q, Chen Q, Zhang H, Xu Z, Wang X, Pang J, Ma J, Ling W, Li D. Associations of serum magnesium levels and calcium-magnesium ratios with mortality in patients with coronary artery disease. Diabetes Metab 2019; 46:384-391. [PMID: 31870835 DOI: 10.1016/j.diabet.2019.12.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 12/05/2019] [Accepted: 12/10/2019] [Indexed: 11/26/2022]
Abstract
AIMS Low magnesium (Mg) and high calcium (Ca) levels are linked to increased cardiovascular disease (CVD) risk in the general population. This prospective study assessed whether there are any independent associations of serum Mg levels and Ca-Mg ratios with mortality in patients with coronary artery disease (CAD). METHODS This prospective cohort study included 3380 CAD patients. Cox regression models were used to estimate associations of serum Mg and Ca-Mg ratio with risk of mortality. RESULTS A total of 562 deaths (331 due to CVD) were recorded during a 7.59-year (median) follow-up. Spline plots displayed U-shaped associations between serum Mg levels and Ca-Mg ratios and risk of mortality. When compared with a moderate group, adjusted hazard ratios (95% confidence intervals) for low Mg levels and high Ca-Mg ratios were 1.59 (1.30-1.95) and 1.31 (1.06-1.61) for all-cause mortality, and 1.71 (1.32-2.22) and 1.44 (1.09-1.89) for CVD mortality, respectively. There was also a tendency to increase risk of mortality in patients with high serum Mg levels and low Ca-Mg ratios. Associations of low serum Mg and high Ca-Mg ratio with risk of mortality did not change when stratified by gender, body mass index, CAD type, estimated glomerular filtration rate, use of diuretics, or history of diabetes or hypertension. CONCLUSION This study demonstrated that a moderate Ca-Mg ratio (range: 3.91-4.70) had the lowest mortality risk, and that low serum Mg and high Ca-Mg ratio were independent risk factors of mortality in CAD patients. Nevertheless, the optimal dose-response of Mg and Ca for mitigating CAD risk still requires further investigation.
Collapse
Affiliation(s)
- Q Li
- Department of Nutrition, School of Public Health, Sun Yat-sen University, 74, Zhongshan Rd 2, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, 510080 Guangzhou, Guangdong Province, PR China
| | - Q Chen
- Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 510120 Guangzhou, Guangdong Province, PR China
| | - H Zhang
- Department of Nutrition, School of Public Health, Sun Yat-sen University, 74, Zhongshan Rd 2, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, 510080 Guangzhou, Guangdong Province, PR China
| | - Z Xu
- Department of Nutrition, School of Public Health, Sun Yat-sen University, 74, Zhongshan Rd 2, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, 510080 Guangzhou, Guangdong Province, PR China
| | - X Wang
- Department of Nutrition, School of Public Health, Sun Yat-sen University, 74, Zhongshan Rd 2, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, 510080 Guangzhou, Guangdong Province, PR China
| | - J Pang
- Department of Nutrition, School of Public Health, Sun Yat-sen University, 74, Zhongshan Rd 2, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, 510080 Guangzhou, Guangdong Province, PR China
| | - J Ma
- Department of Nutrition, School of Public Health, Sun Yat-sen University, 74, Zhongshan Rd 2, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, 510080 Guangzhou, Guangdong Province, PR China
| | - W Ling
- Department of Nutrition, School of Public Health, Sun Yat-sen University, 74, Zhongshan Rd 2, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Engineering Technology Centre of Nutrition Transformation, 510080 Guangzhou, Guangdong Province, PR China.
| | - D Li
- Department of Nutrition, School of Public Health, Sun Yat-sen University, 74, Zhongshan Rd 2, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, 510080 Guangzhou, Guangdong Province, PR China; Guangdong Engineering Technology Centre of Nutrition Transformation, 510080 Guangzhou, Guangdong Province, PR China.
| |
Collapse
|
31
|
Li L, Zhang LP, Han YC, Wang WY, Jin Y, Xia QX, Liu YP, Xiang J, Liu C, Lu SS, Wu W, Chen Z, Pang J, Xi YF, Zheng YS, Gu DM, Fan J, Chang XN, Wang WW, Wang L, Zhang ZH, Yan XC, Sun Y, Li J, Hou F, Zhang JY, Huang RF, Lu JP, Wang Z, Hu YB, Yuan HT, Dong YJ, Wang L, Ke ZY, Geng JS, Guo L, Zhang J, Ying JM. [Consistency of ALK Ventana-D5F3 immunohistochemistry interpretation in lung adenocarcinoma among Chinese histopathologists]. Zhonghua Bing Li Xue Za Zhi 2019; 48:921-927. [PMID: 31818064 DOI: 10.3760/cma.j.issn.0529-5807.2019.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Objective: To understand the consistency of ALK Ventana-D5F3 immunohistochemistry (IHC) interpretation in Chinese lung adenocarcinoma among histopathologists from different hospitals, and to recommend solution for the problems found during the interpretation of ALK IHC in real world, with the aim of the precise selection of patients who can benefit from ALK targeted therapy. Methods: This was a multicenter and retrospective study. A total of 109 lung adenocarcinoma cases with ALK Ventana-D5F3 IHC staining were collected from 31 lung cancer centers in RATICAL research group from January to June in 2018. All cases were scanned into digital imaging with Ventana iSCANcoreo Digital Slide Scanning System and scored by 31 histopathologists from different centers according to ALK binary (positive or negative) interpretation based on its manufacturer's protocol. The cases with high inconsistency rate were further analyzed using FISH/RT-PCR/NGS. Results: There were 49 ALK positive cases and 60 ALK negative cases, confirmed by re-evaluation by the specialist panel. Two cases (No. 2302 and No.2701) scored as positive by local hospitals were rescored as negative, and were confirmed to be negative by RT-PCR/FISH/NGS. The false interpretation rate of these two cases was 58.1% (18/31) and 48.4% (15/31), respectively. Six out of 31 (19.4%) pathologists got 100% accuracy. The minimum consistency between every two pathologists was 75.8%.At least one pathologist gave negative judgement (false negative) or positive judgement (false positive) in the 49 positive or 60 negative cases, accounted for 26.5% (13/49), 41.7% (25/60), respectively, with at least one uncertainty interpretation accounted for 31.2% (34/109). Conclusion: There are certain heterogeneities and misclassifications in the real world interpretation of ALK-D5F3 IHC test, which need to be guided by the oncoming expert consensus based on the real world data.
Collapse
Affiliation(s)
- L Li
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - L P Zhang
- Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
| | - Y C Han
- Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China
| | - W Y Wang
- Department of Pathology, West China Hospital of Sichuan University, Chengdu 610041, China
| | - Y Jin
- Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China
| | - Q X Xia
- Department of Molecular Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - Y P Liu
- Department of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - J Xiang
- Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - C Liu
- Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
| | - S S Lu
- Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - W Wu
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Z Chen
- Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
| | - J Pang
- Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China
| | - Y F Xi
- Department of Pathology, West China Hospital of Sichuan University, Chengdu 610041, China
| | - Y S Zheng
- Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China
| | - D M Gu
- Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China
| | - J Fan
- Department of Molecular Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - X N Chang
- Department of Molecular Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - W W Wang
- Department of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - L Wang
- Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Z H Zhang
- Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
| | - X C Yan
- Institute of Pathology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China
| | - Y Sun
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - J Li
- Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China
| | - F Hou
- Department of Pathology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China
| | - J Y Zhang
- Department of Pathology, West China Hospital of Sichuan University, Chengdu 610041, China
| | - R F Huang
- Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China
| | - J P Lu
- Department of Pathology, Fudan University Cancer Center; Department of Oncology, Shanghai Medical College of Fudan University, Shanghai 200032, China
| | - Z Wang
- Department of Molecular Pathology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China
| | - Y B Hu
- Department of Pathology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
| | - H T Yuan
- Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
| | - Y J Dong
- Department of Pathology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
| | - L Wang
- Department of Pathology, Xijing Hospital, Air Force Military Medical University, Xi'an 710032, China
| | - Z Y Ke
- Department of Pathology, Xijing Hospital, Air Force Military Medical University, Xi'an 710032, China
| | - J S Geng
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - L Guo
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - J Zhang
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - J M Ying
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | | |
Collapse
|
32
|
Pang J, D'Antonio C, Heale E, Boll P, Blake P, Evans JM, Hladunewich M. Provincial Needs Assessment to Determine the Current State of Glomerulonephritis Care in Ontario. Can J Kidney Health Dis 2019; 6:2054358119877405. [PMID: 31565235 PMCID: PMC6755634 DOI: 10.1177/2054358119877405] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Accepted: 07/17/2019] [Indexed: 11/16/2022] Open
Abstract
Background: Despite its relative rarity, glomerulonephritis (GN) accounts for 20% of
prevalent end-stage renal disease patients in Ontario. Early identification
and appropriate management of GN to delay progression of disease can reduce
patient morbidity and health system costs. As such, a provincial GN needs
assessment was conducted to inform on the development of the provincial GN
strategic framework in Ontario. Objective: To understand the current state of GN care in Ontario from nephrologist,
hospital administrator, and patient and family perspectives. Design: Cross-sectional. Settings: 26 regional renal programs in Ontario. Patients: 23 patients and family members living with GN who do not require renal
replacement therapy. Measurements: Patient and family member interviews as well as a survey of
nephrologists. Methods: The study included 3 components: (1) interviews with patients and family
members, (2) a survey of nephrologists, and (3) interviews with regional
renal programs. The Ontario Renal Network provincial office developed the
needs assessment questions and the physician survey questions after
consultation with practicing nephrologists and hospital administrators.
Thematic analysis was used to assess interview data and descriptive
statistics to assess survey data. Results: Interviews with patients and family members (n = 23) identified gaps in care
related to diagnosis and referral to nephrology care, education and
decision-making, and psychosocial supports. The survey of nephrologists (n =
74) identified various issues that contribute to unstandardized GN care
across Ontario, including a lack of provincial expertise in providing
complex GN care, access to medication, multidisciplinary team support as
well as patient education, and psychosocial supports. Interviews with
regional renal programs aligned with interview and survey findings (n =
11). Limitations: Interviews with patients and family members were facilitated by 1 interviewer
and limited to 20 interviews due to resource limitations. All nephrologists,
patients, and family members who participated in the survey and interviews
were volunteers and English-speaking, which may have resulted in
self-selection bias. Conclusions: The provincial GN needs assessment emphasized the necessity to develop and
implement a provincial GN strategy. The strategic framework includes 4
objectives: (1) ensure patients are supported to make informed decisions,
(2) establish a provincial model of care, (3) leverage data to enable
planning, decision-making, and monitoring of outcomes, and (4) ensure
appropriate access to medication. This is the first Ontario strategy to
address provincial gaps in GN care.
Collapse
Affiliation(s)
| | | | - Esti Heale
- Ontario Renal Network, Toronto, ON, Canada
| | - Philip Boll
- Ontario Renal Network, Toronto, ON, Canada.,Division of Nephrology, Trillium Health Partners, Mississauga, ON, Canada
| | - Peter Blake
- Ontario Renal Network, Toronto, ON, Canada.,Division of Nephrology, London Health Sciences Centre, The University of Western Ontario, London, ON, Canada
| | | | - Michelle Hladunewich
- Ontario Renal Network, Toronto, ON, Canada.,Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
33
|
Liang Y, Wang Y, Ma L, Zhong Z, Yang X, Tao X, Chen X, He Z, Yang Y, Zeng K, Kang R, Gong J, Ying S, Lei Y, Pang J, Lv X, Gu Y. Comparison of microRNAs in adipose and muscle tissue from seven indigenous Chinese breeds and Yorkshire pigs. Anim Genet 2019; 50:439-448. [PMID: 31328299 DOI: 10.1111/age.12826] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/24/2019] [Indexed: 01/29/2023]
Abstract
Elucidation of the pig microRNAome is essential for interpreting functional elements of the genome and understanding the genetic architecture of complex traits. Here, we extracted small RNAs from skeletal muscle and adipose tissue, and we compared their expression levels between one Western breed (Yorkshire) and seven indigenous Chinese breeds. We detected the expression of 172 known porcine microRNAs (miRNAs) and 181 novel miRNAs. Differential expression analysis found 92 and 12 differentially expressed miRNAs in adipose and muscle tissue respectively. We found that different Chinese breeds shared common directional miRNA expression changes compared to Yorkshire pigs. Some miRNAs differentially expressed across multiple Chinese breeds, including ssc-miR-129-5p, ssc-miR-30 and ssc-miR-150, are involved in adipose tissue function. Functional enrichment analysis revealed that the target genes of the differentially expressed miRNAs are associated mainly with signaling pathways rather than metabolic and biosynthetic processes. The miRNA-target gene and miRNA-phenotypic traits networks identified many hub miRNAs that regulate a large number of target genes or phenotypic traits. Specifically, we found that intramuscular fat content is regulated by the greatest number of miRNAs in muscle tissue. This study provides valuable new candidate miRNAs that will aid in the improvement of meat quality and production.
Collapse
Affiliation(s)
- Y Liang
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - Y Wang
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - L Ma
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, 610052, Sichuan Province China
| | - Z Zhong
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - X Yang
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - X Tao
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - X Chen
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - Z He
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - Y Yang
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - K Zeng
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - R Kang
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - J Gong
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - S Ying
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - Y Lei
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - J Pang
- Chengdu Biotechservice Institute, Chengdu, 610041, Sichuan Province China
| | - X Lv
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| | - Y Gu
- Animal Breeding and Genetics Key Laboratory of Sichuan Province, Sichuan Animal Science Academy, Chengdu, 610066, Sichuan Province China
| |
Collapse
|
34
|
Thomas C, Stevens R, West L, Oliver E, Pang J, Griffiths H. Performance evaluation of the VITROS® TSH3* assay on the VITROS® 5600/XT7600 integrated and VITROS® 3600 and ECI/ECIQ immunodiagnostic systems. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
35
|
Sun X, Dai X, Pang J, Zhao Y, Ou T, Ma B. CLINICAL OBSERVATION OF METRONOMIC CHEMOTHERAPY COMBINED WITH CLEARING HEAT AND DETOXICATING TRADITIONAL CHINESE MEDICINE IN THE TREATMENT OF REFRACTORY AND RELAPSED ELDERLY LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.123_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- X. Sun
- Hematology Dept; Jiangsu Province Hospital of TCM; Nanjing China
| | - X. Dai
- Hematology Dept; Jiangsu Province Hospital of TCM; Nanjing China
| | - J. Pang
- Hematology Dept; Jiangsu Province Hospital of TCM; Nanjing China
| | - Y. Zhao
- Hematology Dept; Jiangsu Province Hospital of TCM; Nanjing China
| | - T. Ou
- Hematology Dept; Jiangsu Province Hospital of TCM; Nanjing China
| | - B. Ma
- Hematology Dept; Jiangsu Province Hospital of TCM; Nanjing China
| |
Collapse
|
36
|
Pang J, Li CR, Zhao R, Nie TY, Li GQ, Lu X, Hu XX, Wang XK, Yang XY, You XF. Simplified LC-MS/MS method for quantification of IG-105, a novel tubulin ligand, and its application to the pharmacokinetic study in rats at the anticancer effective dose. Pharmazie 2019; 74:79-82. [PMID: 30782255 DOI: 10.1691/ph.2019.8157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
Abstract
IG-105, N-(2, 6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide, a novel carbazole sulfonamide, shows a potent anticancer activity in a variety of human tumor cells in vitro and in vivo. In the present study, a rapid and convenient liquid chromatography/tandem mass spectrometry (LC-MS/MS) method was developed and applied to the pharmacokinetic study of IG-105 in rats. Chromatographic separation was accomplished on a C18 column using an isocratic mobile phase of acetonitrile-water-acetic acid (56:44:0.2, v/v/v). The ion transitions of IG-105 and combretastatin A4 (internal standard) in selected reaction monitoring mode were m/z 398→154 and m/z 317→286, respectively. The assay exhibited good linearity over the range of 2-512 ng/mL. Intra- and inter-day precisions were within 8.2 %, and the accuracies ranged from -6.0 to 3.7 %. The extraction recoveries were higher than 90 %, and the matrix effects were negligible. All quality control samples were stable at different storage conditions. The validated LC-MS/MS method was successfully applied to a preclinical pharmacokinetic study of IG-105 in rats after a single oral dose of 100, 250, or 1000 mg/kg which showed tumor growth inhibition activity. The absorption of IG-105 was proved to be rapid but saturated to a certain extent into the blood circulation, from where it was distributed and eliminated gradually.
Collapse
|
37
|
Gu YL, Pang J, Song JF, Cheng C, Sun ZX. [Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: systematic reviews]. Zhonghua Jie He He Hu Xi Za Zhi 2019; 40:835-844. [PMID: 29320831 DOI: 10.3760/cma.j.issn.1001-0939.2017.11.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the efficacy and safety of anti-Interleukin-5 therapy in patients with asthma. Methods: Data were collected from PubMed, E-Mbase, Springer, Ovid, Cochrane Library, ClinicalTrials.gov, CNKI and Wanfang database (-Feb 2017). Bibliographies of the retrieved articles were checked and analyzed. Results: Twenty publications involving a total of 6 406 patients were used in the analysis, including 23 randomly controlled trials (RCTs) which compared anti-interleukin 5 monoclonal antibody with placebo. Pooled analyses showed that anti-interleukin 5 monoclonal antibody significantly reduced exacerbation risk [RR=0.66, 95%CI(0.59, 0.73)], increased FEV(1)[MD=0.10, 95%CI(0.07, 0.13)] and FEV(1)% predicted [MD=3.90, 95%CI(1.86, 5.95)], and improved the scores on the Asthma Quality of Life Questionnaire (AQLQ) [MD=0.24, 95%CI(0.16, 0.32)]. Anti-interleukin 5 monoclonal antibody was also associated with significantly decreased risk of adverse events than placebo[OR=0.71, 95%CI(0.58, 0.87)]. Conclusion: Anti-interleukin 5 monoclonal antibody reduces the risk of exacerbations and improves quality of life in patients with asthma, and is tolerated well.
Collapse
Affiliation(s)
- Y L Gu
- Department of Pharmacy, the First People's Hospital of Lianyungang, Jiangsu 222001, China
| | | | | | | | | |
Collapse
|
38
|
Vargas García C, Pang J, Watts G. Predictors of a Coronary Artery Calcium Score of Zero in Patients with Familial Hypercholesterolaemia. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Lu J, Zheng M, Kong R, Pang J, Zhu X. Enhancing Solubility of Candesartan Cilexetil by Co-milling; Preparation of Candesartan Cilexetil-glycyrrhizic Acid Composite. Indian J Pharm Sci 2019. [DOI: 10.36468/pharmaceutical-sciences.500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
40
|
Ellis K, Pang J, Watts G. Errors in the imputation of LDL-cholesterol when making a phenotypic diagnosis of familial hypercholesterolaemia in drug treated patients. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
41
|
Kim N, Ngoc N, Pang J, Watts G, Do D, Truong T. Screening and management of familial hypercholesterolemia in Vietnam: Achievements and challenges. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Chan D, Pang J, Hooper A, Bell D, Bates T, Burnett J, Watts G. Diagnostic discordance between the dutch lipid criteria network and simon broome phenotypic diagnostic test for familial hypercholesterolaemia. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
43
|
Vargas garcía C, Pang J, Watts G, Bishop W. Dissociation between coronary artery calcium and cardiovascular risk factors in asymptomatic patients in a risk assessment clinic. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
44
|
Pang J, Vargas-garcia C, Bates T, Abraham A, Watts G. A case-control study of the localisation and composition of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia as assessed by cardiac CT scanning. Atherosclerosis 2018. [DOI: 10.1016/j.atherosclerosis.2018.06.548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
45
|
Shim H, Ma C, Al-Farhan H, Aldarmaki AK, Pang J, Seow C, Fedorak R, Devlin S, Dieleman LA, Kaplan GG, Novak KL, Kroeker KI, Halloran BP, Panaccione R. A107 POSTOPERATIVE OUTCOMES AMONG USTEKINUMAB TREATED CROHN’S DISEASE PATIENTS: A MULTICENTRE CANADIAN PROVINCIAL EXPERIENCE. J Can Assoc Gastroenterol 2018. [DOI: 10.1093/jcag/gwy008.108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- H Shim
- Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada
| | - C Ma
- University of Calgary, Calgary, AB, Canada
| | - H Al-Farhan
- Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada
| | - A K Aldarmaki
- Gastroenterology and Hepatology, University of Calgary, Calgary, AB, Canada
| | - J Pang
- University of Calgary, Calgary, AB, Canada
| | - C Seow
- Medicine, University of Calgary, Calgary, AB, Canada
| | - R Fedorak
- Los Alamos National Laboratory, Edmonton, AB, Canada
| | - S Devlin
- University of Calgary, Calgary, AB, Canada
| | - L A Dieleman
- Medicine, University of Alberta, Edmonton, AB, Canada
| | - G G Kaplan
- Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
| | - K L Novak
- Gastroenterology, University of Calgary, Calgary AB, Canada
| | - K I Kroeker
- Medicine, University of Alberta, Edmonton, AB, Canada
| | - B P Halloran
- Medicine, Divison of Gastroenterology, University Of Alberta, Edmonton, AB, Canada
| | | |
Collapse
|
46
|
Chieng D, Pang J, Hillis G, Watts G, Schultz C. Familial Hypercholesterolaemia and Lipoprotein(A) as Predictors of the Severity and Complexity of Angiographic Lesions in Patients With Premature Coronary Artery Disease. Heart Lung Circ 2018. [DOI: 10.1016/j.hlc.2018.06.716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
47
|
Liu H, Wu Q, Tan HW, Pang J. [The efficacy and safety of coil embolization of septal branch in the treatment of patients with obstructive hypertrophic cardiomyopathy]. Zhonghua Xin Xue Guan Bing Za Zhi 2017; 45:1044-1048. [PMID: 29325364 DOI: 10.3760/cma.j.issn.0253-3758.2017.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To observe the clinical efficacy and safety of coil embolization of septal branch in the treatment of obstructive hypertrophic cardiomyopathy (HOCM). Methods: Eighteen patients with HOCM hospitalized in our department from September 2014 to October 2016 were enrolled in this study. There were 12 males and 6 females in this cohort and the age of patients ranged from 22 to 64 years old. Left ventricular outflow tract gradient (LVOTG) was derived from echocardiographic apical five-chamber view at pre-operation and at 48 hours and 6 months post operation. 24-hour Holter ECG examination was performed to assess the ventricular tachycardia, atrial fibrillation, atrioventricular block at 3 days and 6 months after the interventional operation. Routine ECG and creatine kinase-MB (CK-MB) examination were performed at pre-operation, at 6, 24 and 48 hours post operation. Cardiac troponin T (cTnT) was detected at pre-operation, at 24, 48 hours and 6 days post operation. The clinical symptoms (including chest tightness, chest pain, shortness of breath, syncope) and NYHA classification were assessed at 1, 6 months after the operation by telephone follow-up or outpatient clinic visit. Results: The average preoperative LVOTG detected by cardiac catheter was 103.6 (92.0, 115.0) mmHg (1 mmHg=0.133 kPa) , and the average LVOTG significantly reduced to 44.3 (41.6, 47.2) mmHg immediately after operation (P<0.01). The average ventricular septal thickness at 48 hours (19.2±3.1) mm and 6 months (17.8±2.8) mm after operation tended to be lower than the preoperative ventricular septal thickness ((20.4±3.5) mm, P>0.05). The echocardiographic derived average LVOTG at 48 hours and 6 months after operation was 42.9 (41.1, 45.5) and 39.1 (37.5, 41.0) mmHg, which were significant lower than the preoperative average LVOTG (94.3 (88.5, 101.8) mmHg, both P<0.01). LVOTG at 6 months after operation was significantly lower than that at 48 hours after the operation (P<0.05). The NYHA classification at 6 months after operation was significantly improved compared to pre-operation NYHA classification (P<0.01). During and after the operation, there was no complete atrioventricular block and ventricular tachycardia, no patient developed anterior wall and inferior myocardial infarction. Only one patient experienced transient left bundle branch block. During the 6 months following-up, there was no death, syncope, chest pain, palpitations, shortness of breath, paroxysmal dyspnea and/or lower extremity edema, ventricular tachycardia, atrioventricular block and atrial fibrillation, complete atrioventricular block and ventricular arrhythmia. Conclusion: The coil embolization of septal branch is effective and safe for the treatment of patients with HOCM.
Collapse
Affiliation(s)
- H Liu
- Department of Cardiology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | | | | | | |
Collapse
|
48
|
Tian Y, Zhou S, Yin YH, Zheng YX, Wang RP, Liu XQ, Liu ZQ, Liu QF, Liu W, Pang J, Jiang Z, Tian LH, Huang J, Yang L. [Value of two left atrium and pulmonary vein stereoscopic imaging reconstruction methods on guiding radiofrequency ablation for atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi 2017; 45:930-934. [PMID: 29166718 DOI: 10.3760/cma.j.issn.0253-3758.2017.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To compare the value of two 3D imaging reconstruction methods for left atria and pulmonary vein on guiding the catheter ablation for atrial fibrillation (AF). Methods: From January 2014 to January 2017, a total of 100 drug refractory paroxysmal AF patients were divided into left atria direct angiography group (n=50), and indirect angiography group (n=50). 3D CARTO system was applied for mapping and guiding the ablation procedure. Patients assigned to direct angiography group were treated as follows: intraoperative puncture of atrial septum, inject contrast agent directly into the left atrium, conduct left atrial and pulmonary venous rotation angiography, reconstruct three-dimensional image, integrate the image into real-time X-ray system to facilitate circumferential pulmonary vein isolation. Patients assigned into the indirect angiography group were treated as follows: inject contrast agent through the right ventricle, conduct delayed rotation angiography of the left atria and pulmonary vein to guide circumferential pulmonary vein fixation and ablation. The left atrial and pulmonary venous image acquisition, the operation and X-ray exposure time, the success rate and the incidence of complication of the two groups were compared. The patients were followed up for 3-6 months. Results: General clinical characteristics of the two groups were similar(all P>0.05). Ablation was successful in all 100 patients. The operation time[(112.0±21.4)min vs. (134.0±24.3)min]and X-ray exposure time((10.7±4.7)min vs. (15.8±5.2)min)were significantly lower in direct angiography group than in indirect angiography group (both P<0.01). There was no significant difference between the two groups in the immediate (86%(43/50) vs. 82%(41/50), P=0.59) and short-term (76%(38/50) vs. 72%(36/50), P=0.65) success rate and complication rate (1 aneurysm in the direct angiography group, 1 pericardial tamponade in the indirect angiography group). In-hospital mortality was zero percent. Conclusion: It is safe and effective method to guide the radiofrequency catheter ablation of paroxysmal atrial fibrillation by reconstruction 3D image of left atrium and pulmonary vein. Compared with indirect angiography group, direct angiography group can improve the imaging quality of left atrium and pulmonary vein, decrease the X-ray exposure time of the ablation procedure.
Collapse
Affiliation(s)
- Y Tian
- Department of Cardiology , Guizhou Provincial People's Hospital, People's Hospital of Guizhou Medical University, Guiyang 550002, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Davies A, Dewi F, Pang J, Wright T. Reducing Patient Fasting Time on the Plastic Surgery Trauma List. Int J Surg 2017. [DOI: 10.1016/j.ijsu.2017.08.295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
Pang J, Wang BJ, Li YC, Zhang H, Xiang WP, Hao XW, Xue H. 18 Intermittent hypoxia improves atherosclerosis associated with upregulation of hif-1α and nf-κb in aortic arch and serum of rabbits. J Investig Med 2017. [DOI: 10.1136/jim-2017-mebabstracts.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|